Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

Recent & Breaking News (TSXV:NGEN)

NervGen Pharma Corp. Announces Overnight Marketed Equity Offering

Newsfile May 4, 2021

NervGen Pharma Grants Stock Options

Newsfile April 23, 2021

NervGen Pharma (TSXV:NGEN) appoints Dr. Daniel Mikol as Chief Medical Officer

Julia Kennedy  April 22, 2021

NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer

Newsfile April 22, 2021

NervGen Pharma (TSXV:NGEN) receives approval to begin clinical trial of NVG-291

John Ballem  April 14, 2021

NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291

Newsfile April 14, 2021

NervGen Pharma (TSXV:NGEN) releases 2020 financial results

Jocelyn Aspa April 8, 2021

NervGen Pharma Reports 2020 Year End Results

Newsfile April 8, 2021

NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury

Newsfile March 8, 2021

NervGen Pharma Provides Regulatory Update on Development Program For NVG-291

Newsfile March 4, 2021

NervGen Pharma (TSXV:NGEN) adds Alzheimer’s Disease patient cohort to its clinical trial program

Isabella Zavarise January 27, 2021

NervGen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

Newsfile January 27, 2021

NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board

Newsfile January 26, 2021

NervGen Pharma (TSXV:NGEN) establishes Alzheimer’s Disease scientific advisory board

Isabella Zavarise January 26, 2021

NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Newsfile January 5, 2021

NervGen Pharma Engages CRO for Phase 1 Clinical Trial

Newsfile December 15, 2020

NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update

Newsfile November 19, 2020

NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer's Disease Program and Renews Business Advisory Relationship with Brian McAlister

Newsfile November 10, 2020

NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update

Newsfile October 28, 2020

NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-Dilutive Funding Sources For NVG-291

Newsfile October 19, 2020